Clinical Trial Update: Mass Balance Study of [14C]Chiauranib [NA]

View source ↗

Summary

The mass balance pharmacokinetic study of [14C]Chiauranib has completed for Small cell lung cancer, as reported by Chipscreen Biosciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Chiauranib (Chiauranib)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Small Cell Lung Cancer | NA | Status: COMPLETED